195 related articles for article (PubMed ID: 27567268)
1. Continuous Abstinence During Early Alcohol Treatment is Significantly Associated with Positive Treatment Outcomes, Independent of Duration of Abstinence.
Dunn KE; Harrison JA; Leoutsakos JM; Han D; Strain EC
Alcohol Alcohol; 2017 Jan; 52(1):72-79. PubMed ID: 27567268
[TBL] [Abstract][Full Text] [Related]
2. Cannabis use during treatment for alcohol use disorders predicts alcohol treatment outcomes.
Subbaraman MS; Metrik J; Patterson D; Swift R
Addiction; 2017 Apr; 112(4):685-694. PubMed ID: 27865015
[TBL] [Abstract][Full Text] [Related]
3. Alcohol Use Disorder Treatment: The Association of Pretreatment Use and the Role of Drinking Goal.
Berger L; Brondino M; Fisher M; Gwyther R; Garbutt JC
J Am Board Fam Med; 2016; 29(1):37-49. PubMed ID: 26769876
[TBL] [Abstract][Full Text] [Related]
4. The effects of drinking goal on treatment outcome for alcoholism.
Bujarski S; O'Malley SS; Lunny K; Ray LA
J Consult Clin Psychol; 2013 Feb; 81(1):13-22. PubMed ID: 23231573
[TBL] [Abstract][Full Text] [Related]
5. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
[TBL] [Abstract][Full Text] [Related]
6. Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence.
Fucito LM; Park A; Gulliver SB; Mattson ME; Gueorguieva RV; O'Malley SS
Biol Psychiatry; 2012 Nov; 72(10):832-8. PubMed ID: 22541040
[TBL] [Abstract][Full Text] [Related]
7. Baseline trajectories of drinking moderate acamprosate and naltrexone effects in the COMBINE study.
Gueorguieva R; Wu R; Donovan D; Rounsaville BJ; Couper D; Krystal JH; O'Malley SS
Alcohol Clin Exp Res; 2011 Mar; 35(3):523-31. PubMed ID: 21143249
[TBL] [Abstract][Full Text] [Related]
8. Predictors of abstinence from heavy drinking during treatment in COMBINE and external validation in PREDICT.
Gueorguieva R; Wu R; O'Connor PG; Weisner C; Fucito LM; Hoffmann S; Mann K; O'Malley SS
Alcohol Clin Exp Res; 2014 Oct; 38(10):2647-2656. PubMed ID: 25346505
[TBL] [Abstract][Full Text] [Related]
9. Cravings as a mediator and moderator of drinking outcomes in the COMBINE study.
Subbaraman MS; Lendle S; van der Laan M; Kaskutas LA; Ahern J
Addiction; 2013 Oct; 108(10):1737-44. PubMed ID: 23668624
[TBL] [Abstract][Full Text] [Related]
10. Predictors of pretreatment commitment to abstinence: results from the COMBINE study.
DeMartini KS; Devine EG; DiClemente CC; Martin DJ; Ray LA; O'Malley SS
J Stud Alcohol Drugs; 2014 May; 75(3):438-46. PubMed ID: 24766756
[TBL] [Abstract][Full Text] [Related]
11. Cumulative proportion of responders analysis (CPRA) as a tool to assess treatment outcome in alcohol clinical trials.
Falk DE; Litten RZ; Anton RF; Kranzler HR; Johnson BA;
J Stud Alcohol Drugs; 2014 Mar; 75(2):335-46. PubMed ID: 24650828
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity in pathways to abstinence among women in treatment for alcohol use disorder.
Holzhauer CG; Epstein EE; Cohn AM; McCrady BS; Graff FS; Cook S
J Subst Abuse Treat; 2017 Apr; 75():1-9. PubMed ID: 28237048
[TBL] [Abstract][Full Text] [Related]
13. Results of a double-blind, placebo-controlled pharmacotherapy trial in alcoholism conducted in Germany and comparison with the US COMBINE study.
Mann K; Lemenager T; Hoffmann S; Reinhard I; Hermann D; Batra A; Berner M; Wodarz N; Heinz A; Smolka MN; Zimmermann US; Wellek S; Kiefer F; Anton RF;
Addict Biol; 2013 Nov; 18(6):937-46. PubMed ID: 23231446
[TBL] [Abstract][Full Text] [Related]
14. An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care.
Ernst DB; Pettinati HM; Weiss RD; Donovan DM; Longabaugh R
Ann Fam Med; 2008; 6(5):435-40. PubMed ID: 18779548
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of acamprosate for alcohol dependence in a family medicine setting in the United States: a randomized, double-blind, placebo-controlled study.
Berger L; Fisher M; Brondino M; Bohn M; Gwyther R; Longo L; Beier N; Ford A; Greco J; Garbutt JC
Alcohol Clin Exp Res; 2013 Apr; 37(4):668-74. PubMed ID: 23134193
[TBL] [Abstract][Full Text] [Related]
16. End-of-treatment abstinence self-efficacy, behavioral processes of change, and posttreatment drinking outcomes in Project MATCH.
Crouch TB; DiClemente CC; Pitts SC
Psychol Addict Behav; 2015 Sep; 29(3):706-15. PubMed ID: 25961145
[TBL] [Abstract][Full Text] [Related]
17. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.
Gueorguieva R; Wu R; Tsai WM; O'Connor PG; Fucito L; Zhang H; O'Malley SS
Eur Neuropsychopharmacol; 2015 Oct; 25(10):1586-99. PubMed ID: 26141511
[TBL] [Abstract][Full Text] [Related]
18. Abstinence and low risk drinking during treatment: Association with psychosocial functioning, alcohol use, and alcohol problems 3 years following treatment.
Witkiewitz K; Kirouac M; Roos CR; Wilson AD; Hallgren KA; Bravo AJ; Montes KS; Maisto SA
Psychol Addict Behav; 2018 Sep; 32(6):639-646. PubMed ID: 30160499
[TBL] [Abstract][Full Text] [Related]
19. Examining the daily reciprocal relations between alcohol abstinence self-efficacy and drinking among non-treatment seeking individuals with alcohol use disorder (AUD).
Walsh BE; Manzler CA; Noyes ET; Schlauch RC
Addict Behav; 2024 Sep; 156():108068. PubMed ID: 38772225
[TBL] [Abstract][Full Text] [Related]
20. What happens when people discontinue taking medications? Lessons from COMBINE.
Stout RL; Braciszewski JM; Subbaraman MS; Kranzler HR; O'Malley SS; Falk D;
Addiction; 2014 Dec; 109(12):2044-52. PubMed ID: 25098969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
